Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.
Sponsor: LucasBio
Summary
The goal of this clinical study is to evaluate the safety of cytokine-induced-killer (CIK) cells during early transplant period of autologous hematopoietic stem cell transplant. The main questions it aims to answer are: * What adverse events occur within 2 years following CIK infusion? * Does viral reactivation (CMV, EBV, BKV) occur and lead to infection during the early transplant period of autologous hematopoietic stem cell transplant after CIK infusion? Patients will: * Receive a single infusion of CIK at a dose of 1x10\^9 to 1x10\^10 cells either intravenously or using a central venous catheter within 14±4 days after receiving the autologous hematopoietic stem cell transplantation. * Attend follow-up visits at the clinic for 24 months after the infusion.
Official title: An Investigator's Initiated Clinical Study to Evaluate the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.
Key Details
Gender
All
Age Range
19 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2022-03-28
Completion Date
2026-03-17
Last Updated
2026-07-09
Healthy Volunteers
No
Interventions
CIK cells
Derived from the patient (autologous) prior to autologous hematopoietic stem cell transplantation and administered intravenously as fresh cells at a dose of 1x10\^9 to 1x10\^10 cells over 30 minutes.
Locations (1)
The Catholic University of Korea Seoul St.Mary's Hospital
Seoul, South Korea